
MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the […]